Crossmark

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

Crossref DOI link: https://doi.org/10.1038/s41556-018-0140-1

Published Online: 2018-07-18

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dev, Harveer https://orcid.org/0000-0003-2874-6894
Chiang, Ting-Wei Will

Lescale, Chloe

de Krijger, Inge

Martin, Alistair G.

Pilger, Domenic

Coates, Julia

Sczaniecka-Clift, Matylda

Wei, Wenming

Ostermaier, Matthias

Herzog, Mareike

Lam, Jonathan

Shea, Abigail

Demir, Mukerrem

Wu, Qian

Yang, Fengtang https://orcid.org/0000-0002-3573-2354
Fu, Beiyuan

Lai, Zhongwu

Balmus, Gabriel https://orcid.org/0000-0003-2872-4468
Belotserkovskaya, Rimma

Serra, Violeta https://orcid.org/0000-0001-6620-1065
O’Connor, Mark J.

Bruna, Alejandra

Beli, Petra https://orcid.org/0000-0001-9507-9820
Pellegrini, Luca https://orcid.org/0000-0002-9300-497X
Caldas, Carlos

Deriano, Ludovic https://orcid.org/0000-0002-9673-9525
Jacobs, Jacqueline J. L. https://orcid.org/0000-0002-7704-4795
Galanty, Yaron

Jackson, Stephen P. https://orcid.org/0000-0001-9317-7937
License Information

Text and Data Mining valid from 2018-07-18
More Information

Article History

Received: 27 April 2018

Accepted: 11 June 2018

First Online: 18 July 2018

Competing interests

: S.P.J. receives some research funding from AstraZeneca and is a named inventor on patents describing the use of PARP inhibitors in cancer therapy. V.S.’s laboratory receives research funding support from AstraZeneca. M.O. and Z.L. are employees and shareholders of AstraZeneca.